The Future of Drug Safety

The Future of Drug Safety
Author: Institute of Medicine,Board on Population Health and Public Health Practice,Committee on the Assessment of the US Drug Safety System
Publsiher: National Academies Press
Total Pages: 347
Release: 2007-03-27
Genre: Medical
ISBN: 9780309103046

Download The Future of Drug Safety Book in PDF, Epub and Kindle

In the wake of publicity and congressional attention to drug safety issues, the Food and Drug Administration (FDA) requested the Institute of Medicine assess the drug safety system. The committee reported that a lack of clear regulatory authority, chronic underfunding, organizational problems, and a scarcity of post-approval data about drugs' risks and benefits have hampered the FDA's ability to evaluate and address the safety of prescription drugs after they have reached the market. Noting that resources and therefore efforts to monitor medications' riskâ€"benefit profiles taper off after approval, The Future of Drug Safety offers a broad set of recommendations to ensure that consideration of safety extends from before product approval through the entire time the product is marketed and used.

Challenges for the FDA

Challenges for the FDA
Author: Institute of Medicine,Board on Health Sciences Policy,Forum on Drug Discovery, Development, and Translation
Publsiher: National Academies Press
Total Pages: 128
Release: 2007-10-02
Genre: Medical
ISBN: 9780309179447

Download Challenges for the FDA Book in PDF, Epub and Kindle

As the principal agency regulating food, drugs, medical devices, and biological products used by Americans, the U.S. Food and Drug Administration (FDA) serves one of the most critical consumer protection functions of the federal government. The FDA's reach is enormous, regulating products that represent roughly 25 percent of all consumer spending in the United States. Since 1992, however, federal funding for the agency has diminished, and the FDA's Center for Drug Evaluation and Research (CDER) currently relies on the fees it receives from the industry it regulates to fund the majority of its drug regulation functions. Prescription drug safety is receiving heightened press coverage and congressional scrutiny as a result of recent, highly publicized events, such as the recall of Vioxx because of its link to heart attacks, and the link between certain antidepressants (selective serotonin reuptake inhibitors, or SSRIs) and an increased risk of suicidal ideation in children. To address these concerns, the FDA in 2005 commissioned the Institute of Medicine (IOM) to conduct an independent assessment of the current U.S. drug safety system. In September 2006, the IOM committee released its report-The Future of Drug Safety: Promoting and Protecting the Health of the Public-which included 25 recommendations for improving the system for drug safety review. The committee identified four major vulnerabilities in the U.S. drug safety system: (1) chronic underfunding; (2) organization problems, particularly inadequate integration of pre-and postmarket data review; (3) a range of technical problems related to the insufficient quantity and quality of postmarket data and inadequate capability to systematically monitor the risks and benefits of drugs after marketing; and (4) unclear regulatory authority and insufficiently flexible regulatory tools. Since the IOM report was issued, the FDA has taken a number of steps toward implementing the recommended improvements. Like many government agencies, however, the FDA is financially strained by its existing responsibilities, and fully implementing the recommended improvements to the drug safety system would require significant financial commitments.The IOM report addressed some of the costs associated with its recommendations, but left many unanswered questions about the resources required to fully achieve the envisioned improvements. To better understand the types and magnitude of resources required to achieve the goals of the IOM report, the IOM's Forum on Drug Discovery, Development, and Translation convened a 1-day symposium in March 2007. Challenges for the FDA: The Future of Drug Safety, Workshop Summary explains the presentations and discussions in seven key areas: addressing the FDA's resource challenges; strengthening the scientific base of the agency; integrating pre- and postmarket review; enhancing postmarket safety monitoring; conducting confirmatory drug safety and efficacy studies; enhancing the value of clinical trial registration; and enhancing the FDA's postmarket regulation and enforcement.

New Insights into the Future of Pharmacoepidemiology and Drug Safety

New Insights into the Future of Pharmacoepidemiology and Drug Safety
Author: Maria Teresa Herdeiro,Fátima Roque,Tânia Magalhães Silva,Adolfo Figueiras
Publsiher: BoD – Books on Demand
Total Pages: 202
Release: 2021-10-13
Genre: Medical
ISBN: 9781839685965

Download New Insights into the Future of Pharmacoepidemiology and Drug Safety Book in PDF, Epub and Kindle

In the last decade, pharmacoepidemiology has emerged as an important field to study the use/effects of drugs in large populations in real life, allowing for improved benefits and effectiveness of drugs as well as a decline in drug-related risks. The correct assessment, reporting, monitoring, and prevention of adverse events in drugs’ development, as well as therapy and post-market surveillance, is essential to improve clinical therapies and health outcomes. This book provides a comprehensive and unique overview of the relevance, new insights, and recent findings of pharmacoepidemiology and drug safety in public health.

Improving Drug Safety A Joint Responsibility

Improving Drug Safety     A Joint Responsibility
Author: Rolf Dinkel,Bruno Horisberger,Kenneth W. Tolo
Publsiher: Springer Science & Business Media
Total Pages: 338
Release: 2013-03-07
Genre: Medical
ISBN: 9783642612503

Download Improving Drug Safety A Joint Responsibility Book in PDF, Epub and Kindle

As the focus on pharmaceuticals has broadened from concern for their cost and effectiveness to their real and potential risks and benefits, a critical question has been raised: whose responsibility is it to improve drug safety? In April 1990, this question became the theme for a conference at Wolfsberg, Switzerland, near the shores of Lake Constance. Called an "international dialogue conference" by its organizers, the meeting brought together leaders from the pharmaceutical industry, regulatory authorities, academia, medicine, consumer organizations and the media. Opening addresses were given by representatives of the Council for International Organizations of Medical Sciences (CIOMS), the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), the Swiss International Pharmaceutical Agency, and the RAD-AR Consortium. This book documents the papers presented and discussions held at this conference, which took the topic of risks and benefits of drug therapy one step further to responsibility. It includes a rich menu of issues for those who care about the evaluation of drug therapy, the ethics behind it, the expectations of the patient, and the role of traditional and nontraditional drug safety communica tions. The ideas expressed here come from different parts of the world but relate to common drug safety problems, observations, and scientific assessments; they provide insights into innovative approaches, cautious changes, and desired actions. The papers in this volume are broadly divided into conceptual perspectives (ethics, how the knowledge about drug risks and benefits is generated and appraised, the expectations in drug safety) and operational perspectives (communication, discussion, and action).

Ethical and Scientific Issues in Studying the Safety of Approved Drugs

Ethical and Scientific Issues in Studying the Safety of Approved Drugs
Author: Institute of Medicine,Board on Population Health and Public Health Practice,Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs
Publsiher: National Academies Press
Total Pages: 292
Release: 2012-07-30
Genre: Medical
ISBN: 9780309218160

Download Ethical and Scientific Issues in Studying the Safety of Approved Drugs Book in PDF, Epub and Kindle

An estimated 48 percent of the population takes at least one prescription drug in a given month. Drugs provide great benefits to society by saving or improving lives. Many drugs are also associated with side effects or adverse events, some serious and some discovered only after the drug is on the market. The discovery of new adverse events in the postmarketing setting is part of the normal natural history of approved drugs, and timely identification and warning about drug risks are central to the mission of the Food and Drug Administration (FDA). Not all risks associated with a drug are known at the time of approval, because safety data are collected from studies that involve a relatively small number of human subjects during a relatively short period. Written in response to a request by the FDA, Ethical and Scientific Issues in Studying the Safety of Approved Drugs discusses ethical and informed consent issues in conducting studies in the postmarketing setting. It evaluates the strengths and weaknesses of various approaches to generate evidence about safety questions, and makes recommendations for appropriate followup studies and randomized clinical trials. The book provides guidance to the FDA on how it should factor in different kinds of evidence in its regulatory decisions. Ethical and Scientific Issues in Studying the Safety of Approved Drugs will be of interest to the pharmaceutical industry, patient advocates, researchers, and consumer groups.

Technology for Drug Safety

Technology for Drug Safety
Author: Yaser Mohammed Al-Worafi
Publsiher: Unknown
Total Pages: 0
Release: 2023
Genre: Electronic Book
ISBN: 3031342690

Download Technology for Drug Safety Book in PDF, Epub and Kindle

This book presents information about the use of technology to support the prevention and management of drug safety issues: pharmacovigilance (PV), medication errors, drug-related problems (DRPs), counterfeit medicines and other drug safety issues. Adapting new technologies/information technologies, mobile technologies and social media has contributed effectively to safety practices for medications, with this book providing comprehensive information as a guide to its challenges and potential. Technology for Drug Safety provides practicing and trainee pharmacists, pharmacy technicians, pharmacy educators, researchers, public health policy makers, healthcare professionals and medical educators with vital information about the impact of technology on drug safety-related issues. It describes the current status of the practice, the challenges in the field and recommendations for the effective use of technology in drug safety practice including clinical trials and drug development, PV, detection of adverse drug reactions, reporting and management, medication errors detection, reporting and management, DRPs, counterfeit and substandard medications, and other safety issues.

The Future of Drug Discovery

The Future of Drug Discovery
Author: Tamas Bartfai,Graham V. Lees
Publsiher: Academic Press
Total Pages: 376
Release: 2013-05-18
Genre: Medical
ISBN: 9780124095199

Download The Future of Drug Discovery Book in PDF, Epub and Kindle

The Future of Drug Discovery: Who decides which diseases to treat? provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. The authors posit that as a result of increasing risk aversion and accelerated savings in research and development, the industry is not developing drugs for increasingly prevalent diseases, such as Alzheimer’s disease, untreatable pain, antibiotics and more. This book carefully exposes the gap between the medicines and therapies we need and the current business path. By analyzing the situation and discussing prospects for the next decade, the The Future of Drug Discovery is a timely book for all those who care about the development needs for drugs for disease. Provides an in-depth, broad perspective on the crisis in drug industry Exposes the disconnect between what society needs and what the drug companies are working on Analyses and projects over 10 years into the future Explains what it means for scientists and society Determines what is needed to be done to make sure that the industry responds to society's needs, remains commercially attractive and answers the question as to who decides which diseases to treat

The Future of Drug Safety Promoting and Protecting the Health of the Public

The Future of Drug Safety  Promoting and Protecting the Health of the Public
Author: Anonim
Publsiher: Unknown
Total Pages: 0
Release: 2007
Genre: Drugs
ISBN: OCLC:123546928

Download The Future of Drug Safety Promoting and Protecting the Health of the Public Book in PDF, Epub and Kindle